Erez Vigodman steps down as Teva CEO

7 February 2017

Erez Vigodman is stepping down from his post as chief executive of Teva Pharmaceutical Industries (NYSE: TEVA) “by mutual agreement,” the Israeli generics giant announced late Monday, without giving any specific reason for the decision.

Dr Yitzhak Peterburg, who has served as chairman of the Teva board of directors since January 2015, has been appointed interim president and chief executive, effective immediately. Mr Vigodman’s service on the Teva board has also ended.

Mr Vigodman only took on the CEO role in February 2014, succeeding Jeremy Levin, who also left after a short time in the position due to a falling out with Teva's board.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK